CA2575411A1 - Thiazole derivatives having vap-1 inhibitory activity - Google Patents
Thiazole derivatives having vap-1 inhibitory activity Download PDFInfo
- Publication number
- CA2575411A1 CA2575411A1 CA002575411A CA2575411A CA2575411A1 CA 2575411 A1 CA2575411 A1 CA 2575411A1 CA 002575411 A CA002575411 A CA 002575411A CA 2575411 A CA2575411 A CA 2575411A CA 2575411 A1 CA2575411 A1 CA 2575411A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- methyl
- thiazol
- ethyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002401 inhibitory effect Effects 0.000 title description 4
- 101000774560 Crotalus atrox Zinc metalloproteinase-disintegrin-like VAP1 Proteins 0.000 title 1
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 186
- 102100027159 Membrane primary amine oxidase Human genes 0.000 claims abstract description 99
- 101710132836 Membrane primary amine oxidase Proteins 0.000 claims abstract description 97
- 150000003839 salts Chemical class 0.000 claims abstract description 56
- 239000003112 inhibitor Substances 0.000 claims abstract description 53
- 201000010099 disease Diseases 0.000 claims abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 47
- 208000001344 Macular Edema Diseases 0.000 claims abstract description 37
- 206010025415 Macular oedema Diseases 0.000 claims abstract description 37
- 201000010230 macular retinal edema Diseases 0.000 claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- -1 3-(methanesulfonyl)benzyl Chemical group 0.000 claims description 103
- 206010012601 diabetes mellitus Diseases 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 37
- 125000002947 alkylene group Chemical group 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 21
- 206010038923 Retinopathy Diseases 0.000 claims description 20
- 201000001320 Atherosclerosis Diseases 0.000 claims description 18
- 208000027866 inflammatory disease Diseases 0.000 claims description 18
- 201000008482 osteoarthritis Diseases 0.000 claims description 18
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 16
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 16
- 201000011190 diabetic macular edema Diseases 0.000 claims description 16
- 208000017442 Retinal disease Diseases 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 230000002792 vascular Effects 0.000 claims description 14
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 13
- 239000005977 Ethylene Substances 0.000 claims description 13
- 206010020772 Hypertension Diseases 0.000 claims description 12
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 12
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 12
- 206010003246 arthritis Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 12
- 208000010125 myocardial infarction Diseases 0.000 claims description 12
- 208000003265 stomatitis Diseases 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 10
- PQEFJKLVFBMTHJ-MRXNPFEDSA-N (3r)-1-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n,n-dimethylpyrrolidine-3-carboxamide Chemical compound C1[C@H](C(=O)N(C)C)CCN1CC1=C(CCC=2C=CC(NC(N)=N)=CC=2)N=C(NC(C)=O)S1 PQEFJKLVFBMTHJ-MRXNPFEDSA-N 0.000 claims description 8
- CEMZPAYDPVUXTQ-UHFFFAOYSA-N 2-[4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl]-n-(diaminomethylidene)acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CC(=O)NC(N)=N)=CC=2)=C1 CEMZPAYDPVUXTQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- BSVWJVLQYMYFOA-UHFFFAOYSA-N n-[4-[4-[4-(diaminomethylideneamino)butyl]phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CCCCNC(N)=N)=CC=2)=C1 BSVWJVLQYMYFOA-UHFFFAOYSA-N 0.000 claims description 7
- FQXLIWSJRXSZBZ-UHFFFAOYSA-N n-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n-methyl-4-nitrobenzamide Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(=O)N(C)CC=1SC(NC(C)=O)=NC=1CCC1=CC=C(NC(N)=N)C=C1 FQXLIWSJRXSZBZ-UHFFFAOYSA-N 0.000 claims description 7
- PQEFJKLVFBMTHJ-INIZCTEOSA-N (3s)-1-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n,n-dimethylpyrrolidine-3-carboxamide Chemical compound C1[C@@H](C(=O)N(C)C)CCN1CC1=C(CCC=2C=CC(NC(N)=N)=CC=2)N=C(NC(C)=O)S1 PQEFJKLVFBMTHJ-INIZCTEOSA-N 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 6
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 6
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 6
- 208000037157 Azotemia Diseases 0.000 claims description 6
- 201000004569 Blindness Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000025985 Central nervous system inflammatory disease Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims description 6
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 6
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 208000003790 Foot Ulcer Diseases 0.000 claims description 6
- 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 claims description 6
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 6
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 6
- 206010054805 Macroangiopathy Diseases 0.000 claims description 6
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 6
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 206010065159 Polychondritis Diseases 0.000 claims description 6
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 6
- 206010036105 Polyneuropathy Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 208000003782 Raynaud disease Diseases 0.000 claims description 6
- 208000033464 Reiter syndrome Diseases 0.000 claims description 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 6
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 6
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 206010047115 Vasculitis Diseases 0.000 claims description 6
- 210000001789 adipocyte Anatomy 0.000 claims description 6
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 230000004075 alteration Effects 0.000 claims description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- 238000002266 amputation Methods 0.000 claims description 6
- 208000021328 arterial occlusion Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 230000023852 carbohydrate metabolic process Effects 0.000 claims description 6
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims description 6
- 230000003915 cell function Effects 0.000 claims description 6
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 210000002808 connective tissue Anatomy 0.000 claims description 6
- 208000010247 contact dermatitis Diseases 0.000 claims description 6
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 201000001981 dermatomyositis Diseases 0.000 claims description 6
- 210000003038 endothelium Anatomy 0.000 claims description 6
- 230000003176 fibrotic effect Effects 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 6
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 201000006370 kidney failure Diseases 0.000 claims description 6
- 230000003902 lesion Effects 0.000 claims description 6
- 201000011486 lichen planus Diseases 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 201000005518 mononeuropathy Diseases 0.000 claims description 6
- 210000002200 mouth mucosa Anatomy 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- ILFPDJANERMNPA-UHFFFAOYSA-N n-[4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-5-[(4-sulfamoylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=1C=C(S(N)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(NC(N)=N)C=C1 ILFPDJANERMNPA-UHFFFAOYSA-N 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 206010035114 pityriasis rosea Diseases 0.000 claims description 6
- 206010035116 pityriasis rubra pilaris Diseases 0.000 claims description 6
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 6
- 208000005987 polymyositis Diseases 0.000 claims description 6
- 230000007824 polyneuropathy Effects 0.000 claims description 6
- 230000002685 pulmonary effect Effects 0.000 claims description 6
- 208000002574 reactive arthritis Diseases 0.000 claims description 6
- 230000000306 recurrent effect Effects 0.000 claims description 6
- 208000009169 relapsing polychondritis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 206010043207 temporal arteritis Diseases 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 6
- 208000009852 uremia Diseases 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 5
- OYSAISOGWWMOSE-UHFFFAOYSA-N n-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n-methyl-4-methylsulfonylbenzamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(=O)N(C)CC=1SC(NC(C)=O)=NC=1CCC1=CC=C(NC(N)=N)C=C1 OYSAISOGWWMOSE-UHFFFAOYSA-N 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 208000027496 Behcet disease Diseases 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 273
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 266
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 200
- 238000005160 1H NMR spectroscopy Methods 0.000 description 180
- 238000004519 manufacturing process Methods 0.000 description 180
- 239000000203 mixture Substances 0.000 description 180
- 239000000243 solution Substances 0.000 description 148
- 239000011541 reaction mixture Substances 0.000 description 131
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 108
- 239000007787 solid Substances 0.000 description 97
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 84
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 78
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 76
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- 239000012299 nitrogen atmosphere Substances 0.000 description 60
- 239000003480 eluent Substances 0.000 description 57
- 239000000741 silica gel Substances 0.000 description 56
- 229910002027 silica gel Inorganic materials 0.000 description 56
- 229960001866 silicon dioxide Drugs 0.000 description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 55
- 239000012044 organic layer Substances 0.000 description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 49
- 238000006243 chemical reaction Methods 0.000 description 49
- 235000019439 ethyl acetate Nutrition 0.000 description 47
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 46
- 229940093499 ethyl acetate Drugs 0.000 description 46
- 101150041968 CDC13 gene Proteins 0.000 description 44
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 40
- 239000012267 brine Substances 0.000 description 39
- 238000001914 filtration Methods 0.000 description 39
- 238000003818 flash chromatography Methods 0.000 description 39
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 39
- 235000019341 magnesium sulphate Nutrition 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- 239000011734 sodium Substances 0.000 description 35
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 34
- 239000003921 oil Substances 0.000 description 33
- 239000002244 precipitate Substances 0.000 description 32
- 239000000706 filtrate Substances 0.000 description 31
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 31
- 239000002904 solvent Substances 0.000 description 27
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 23
- 239000000843 powder Substances 0.000 description 23
- 239000000725 suspension Substances 0.000 description 23
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 17
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 238000001816 cooling Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000006260 foam Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000003039 volatile agent Substances 0.000 description 12
- 239000010779 crude oil Substances 0.000 description 11
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 10
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000012346 acetyl chloride Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000002198 insoluble material Substances 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 7
- KBQWZCGLPJQCAU-UHFFFAOYSA-N n-(4-formyl-1,3-thiazol-2-yl)acetamide Chemical compound CC(=O)NC1=NC(C=O)=CS1 KBQWZCGLPJQCAU-UHFFFAOYSA-N 0.000 description 7
- YVYPEAZIGLTXSP-DJWKRKHSSA-N n-[4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(\C=C/C=2C=CC(=CC=2)[N+]([O-])=O)=C1 YVYPEAZIGLTXSP-DJWKRKHSSA-N 0.000 description 7
- QFNFDHNZVTWZED-UHFFFAOYSA-N tert-butyl n-[[(2-methylpropan-2-yl)oxycarbonylamino]-pyrazol-1-ylmethylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NC(=O)OC(C)(C)C)N1C=CC=N1 QFNFDHNZVTWZED-UHFFFAOYSA-N 0.000 description 7
- WUYLHICHUYNPNZ-UHFFFAOYSA-N (2-acetamido-1,3-thiazol-4-yl)methyl acetate Chemical compound CC(=O)NC1=NC(COC(C)=O)=CS1 WUYLHICHUYNPNZ-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
- XRXOHGHYAPSJAV-UHFFFAOYSA-N n-[4-(hydroxymethyl)-1,3-thiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC(CO)=CS1 XRXOHGHYAPSJAV-UHFFFAOYSA-N 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 5
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- HJEDHGJBNGCNAN-UHFFFAOYSA-N (2-amino-1,3-thiazol-4-yl)methyl acetate;hydrochloride Chemical compound Cl.CC(=O)OCC1=CSC(N)=N1 HJEDHGJBNGCNAN-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- RUJGVKORXDOSBT-UHFFFAOYSA-N n-[4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(N)=CC=2)=C1 RUJGVKORXDOSBT-UHFFFAOYSA-N 0.000 description 4
- MVESDSWTNCLUPC-UHFFFAOYSA-N n-[4-[2-[4-(2-aminoethyl)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCN)=CC=2)=C1 MVESDSWTNCLUPC-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000011149 sulphuric acid Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- LCMPIWIWBGHBOY-UHFFFAOYSA-N (3-chloro-2-oxopropyl) acetate Chemical compound CC(=O)OCC(=O)CCl LCMPIWIWBGHBOY-UHFFFAOYSA-N 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- PUPQZNNTHMAASA-IZZDOVSWSA-N 4-[[2-acetamido-4-[(e)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-5-yl]methyl]benzenesulfonyl chloride Chemical compound C=1C=C(S(Cl)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 PUPQZNNTHMAASA-IZZDOVSWSA-N 0.000 description 3
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 3
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 3
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 3
- 239000012448 Lithium borohydride Substances 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- HPFCLDHQJUNWQD-UHFFFAOYSA-N [4-(carboxymethyl)phenyl]methyl-triphenylphosphanium;bromide Chemical compound [Br-].C1=CC(CC(=O)O)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 HPFCLDHQJUNWQD-UHFFFAOYSA-N 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- LGPRETRHIITWOD-BUHFOSPRSA-N ethyl (e)-3-[2-acetamido-4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethyl]-1,3-thiazol-5-yl]prop-2-enoate Chemical compound S1C(NC(C)=O)=NC(CCC=2C=CC(NC(=O)OC(C)(C)C)=CC=2)=C1/C=C/C(=O)OCC LGPRETRHIITWOD-BUHFOSPRSA-N 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- YKAPULHPFXBSFR-UHFFFAOYSA-N methyl 3-[4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1CCC1=CSC(NC(C)=O)=N1 YKAPULHPFXBSFR-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- DNKKAVZNKMCFPB-UHFFFAOYSA-N n-[4-formyl-5-[(4-methylsulfanylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(SC)=CC=C1CC1=C(C=O)N=C(NC(C)=O)S1 DNKKAVZNKMCFPB-UHFFFAOYSA-N 0.000 description 3
- YXETWYWTBPFJOY-YVMONPNESA-N n-[5-(methylaminomethyl)-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(C)=O)=NC(\C=C/C=2C=CC(=CC=2)[N+]([O-])=O)=C1CNC YXETWYWTBPFJOY-YVMONPNESA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 3
- RCCCKRLZQBQNPW-UHFFFAOYSA-N (2,3-dinitrophenyl)methanol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O RCCCKRLZQBQNPW-UHFFFAOYSA-N 0.000 description 2
- OJRGLKLQRMKAMX-UHFFFAOYSA-M (2,3-dinitrophenyl)methyl-triphenylphosphanium;bromide Chemical compound [Br-].[O-][N+](=O)C1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1[N+]([O-])=O OJRGLKLQRMKAMX-UHFFFAOYSA-M 0.000 description 2
- JVDHLRACASTEFG-UHFFFAOYSA-N (2,6-dibutoxyphenyl)methanamine Chemical compound CCCCOC1=CC=CC(OCCCC)=C1CN JVDHLRACASTEFG-UHFFFAOYSA-N 0.000 description 2
- HXYQXLFSLITFSL-UHFFFAOYSA-N (2,6-diethoxyphenyl)methanamine Chemical compound CCOC1=CC=CC(OCC)=C1CN HXYQXLFSLITFSL-UHFFFAOYSA-N 0.000 description 2
- HIXZJPWRAALXBT-UHFFFAOYSA-N (2,6-diethylphenyl)methanamine Chemical compound CCC1=CC=CC(CC)=C1CN HIXZJPWRAALXBT-UHFFFAOYSA-N 0.000 description 2
- WBJSFNLJWDAPGF-UHFFFAOYSA-N (2,6-dipropoxyphenyl)methanamine Chemical compound CCCOC1=CC=CC(OCCC)=C1CN WBJSFNLJWDAPGF-UHFFFAOYSA-N 0.000 description 2
- WRVDRSYYPFSEQZ-UHFFFAOYSA-N (2,6-dipropylphenyl)methanamine Chemical compound CCCC1=CC=CC(CCC)=C1CN WRVDRSYYPFSEQZ-UHFFFAOYSA-N 0.000 description 2
- ITPGGUNSUDNGRY-UHFFFAOYSA-N (2-acetamido-1,3-thiazol-4-yl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].S1C(NC(=O)C)=NC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ITPGGUNSUDNGRY-UHFFFAOYSA-N 0.000 description 2
- 150000005068 1,3,4-oxadiazines Chemical class 0.000 description 2
- FYIDYFJAULNUBI-UHFFFAOYSA-N 1-(bromomethyl)-2,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(CBr)=C1[N+]([O-])=O FYIDYFJAULNUBI-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- VYVXSFNSQXKFMI-UHFFFAOYSA-N 1-amino-4-[4-(2-amino-1,3-thiazol-4-yl)phenyl]butan-2-one;dihydrochloride Chemical compound Cl.Cl.C1=CC(CCC(=O)CN)=CC=C1C1=CSC(N)=N1 VYVXSFNSQXKFMI-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- PTTFLKHCSZSFOL-UHFFFAOYSA-N 2-(3-bromophenyl)ethanol Chemical compound OCCC1=CC=CC(Br)=C1 PTTFLKHCSZSFOL-UHFFFAOYSA-N 0.000 description 2
- HRFLXGYDQUBZCO-UHFFFAOYSA-N 2-(3-bromophenyl)ethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCC1=CC=CC(Br)=C1 HRFLXGYDQUBZCO-UHFFFAOYSA-N 0.000 description 2
- JDPDXEGVVCCIMH-UHFFFAOYSA-N 2-[2-(aminomethyl)-3-(2-hydroxyethoxy)phenoxy]ethanol Chemical compound NCC1=C(OCCO)C=CC=C1OCCO JDPDXEGVVCCIMH-UHFFFAOYSA-N 0.000 description 2
- WUKCUUPBPWRQKR-FMIVXFBMSA-N 2-[4-[(e)-2-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]ethenyl]phenyl]acetic acid Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1\C=C\C1=CC=C(CC(O)=O)C=C1 WUKCUUPBPWRQKR-FMIVXFBMSA-N 0.000 description 2
- ZEXMUXOCMYAHLH-UHFFFAOYSA-N 2-[4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl]acetic acid Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CC(O)=O)=CC=2)=C1 ZEXMUXOCMYAHLH-UHFFFAOYSA-N 0.000 description 2
- WPKHLBAYBOADOZ-UHFFFAOYSA-N 2-[4-[2-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]ethyl]phenyl]-n-(diaminomethylidene)acetamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(CC(=O)NC(N)=N)C=C1 WPKHLBAYBOADOZ-UHFFFAOYSA-N 0.000 description 2
- NOZOLHYYYZNLCW-UHFFFAOYSA-N 2-[4-[2-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]ethyl]phenyl]acetic acid Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(CC(O)=O)C=C1 NOZOLHYYYZNLCW-UHFFFAOYSA-N 0.000 description 2
- CJHCOAWTCPYVHG-UHFFFAOYSA-N 3-[4-(2-acetamido-1,3-thiazol-4-yl)phenyl]propanoic acid Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CCC(O)=O)=CC=2)=C1 CJHCOAWTCPYVHG-UHFFFAOYSA-N 0.000 description 2
- PWTMJIAJPCGXAC-UHFFFAOYSA-N 3-[4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl]propanoic acid Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCC(O)=O)=CC=2)=C1 PWTMJIAJPCGXAC-UHFFFAOYSA-N 0.000 description 2
- OZRFRWFTQLTERV-UHFFFAOYSA-N 3-[4-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]phenyl]propanoic acid Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CCC(O)=O)=CC=2)=C1CC1=CC=C(S(C)(=O)=O)C=C1 OZRFRWFTQLTERV-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- GDHDXLLZNZUKGT-UHFFFAOYSA-N 4-[2-(1,3-dioxoisoindol-2-yl)ethyl]benzaldehyde Chemical compound C1=CC(C=O)=CC=C1CCN1C(=O)C2=CC=CC=C2C1=O GDHDXLLZNZUKGT-UHFFFAOYSA-N 0.000 description 2
- HMMXTXQMFIQXRD-UHFFFAOYSA-N 4-[4-(2-acetamido-1,3-thiazol-4-yl)phenyl]butyl 2,2-dimethylpropanoate Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CCCCOC(=O)C(C)(C)C)=CC=2)=C1 HMMXTXQMFIQXRD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- CBQYNPHHHJTCJS-UHFFFAOYSA-N Alline Chemical compound C1=CC=C2C3(O)CCN(C)C3NC2=C1 CBQYNPHHHJTCJS-UHFFFAOYSA-N 0.000 description 2
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- DHAOFTIZBAHSMV-UHFFFAOYSA-N N-fluoroprop-2-en-1-amine Chemical class FNCC=C DHAOFTIZBAHSMV-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 239000012425 OXONE® Substances 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- JNGIBXKJBVBIGJ-UHFFFAOYSA-N [2,6-bis(methoxymethoxy)phenyl]methanamine Chemical compound COCOC1=CC=CC(OCOC)=C1CN JNGIBXKJBVBIGJ-UHFFFAOYSA-N 0.000 description 2
- SHSMPHBXSMDTRH-UHFFFAOYSA-N [2,6-bis(methoxymethyl)phenyl]methanamine Chemical compound COCC1=CC=CC(COC)=C1CN SHSMPHBXSMDTRH-UHFFFAOYSA-N 0.000 description 2
- IQLJYRVOZQERBH-UHFFFAOYSA-N [2,6-di(propan-2-yloxy)phenyl]methanamine Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1CN IQLJYRVOZQERBH-UHFFFAOYSA-N 0.000 description 2
- HEOUPMVRBZCBRF-UHFFFAOYSA-M [2-(4-ethoxycarbonylphenyl)-2-oxoethyl]-triphenylphosphanium;bromide Chemical compound [Br-].C1=CC(C(=O)OCC)=CC=C1C(=O)C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 HEOUPMVRBZCBRF-UHFFFAOYSA-M 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- LOYSBJJGNUPDMW-ZHACJKMWSA-N ethyl (e)-3-[2-acetamido-4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-5-yl]prop-2-enoate Chemical compound S1C(NC(C)=O)=NC(CCC=2C=CC(N)=CC=2)=C1/C=C/C(=O)OCC LOYSBJJGNUPDMW-ZHACJKMWSA-N 0.000 description 2
- KJKCGBJTNCTYIR-WUKNDPDISA-N ethyl (e)-3-[2-acetamido-4-[2-[4-[[n,n'-bis[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]amino]phenyl]ethyl]-1,3-thiazol-5-yl]prop-2-enoate Chemical compound S1C(NC(C)=O)=NC(CCC=2C=CC(N\C(NC(=O)OC(C)(C)C)=N\C(=O)OC(C)(C)C)=CC=2)=C1/C=C/C(=O)OCC KJKCGBJTNCTYIR-WUKNDPDISA-N 0.000 description 2
- HPEFLTBLLFQHLA-VAWYXSNFSA-N ethyl (e)-3-[4-[3-(2-acetamido-1,3-thiazol-4-yl)propyl]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OCC)=CC=C1CCCC1=CSC(NC(C)=O)=N1 HPEFLTBLLFQHLA-VAWYXSNFSA-N 0.000 description 2
- LGPRETRHIITWOD-YPKPFQOOSA-N ethyl (z)-3-[2-acetamido-4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethyl]-1,3-thiazol-5-yl]prop-2-enoate Chemical compound S1C(NC(C)=O)=NC(CCC=2C=CC(NC(=O)OC(C)(C)C)=CC=2)=C1\C=C/C(=O)OCC LGPRETRHIITWOD-YPKPFQOOSA-N 0.000 description 2
- KMRBVHNWKFOXEC-UHFFFAOYSA-N ethyl 2-acetamido-4-(chloromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(NC(C)=O)=NC=1CCl KMRBVHNWKFOXEC-UHFFFAOYSA-N 0.000 description 2
- OBIIWXHXIQXEHF-UHFFFAOYSA-N ethyl 2-acetamido-4-[2-(4-aminophenyl)ethyl]-1,3-thiazole-5-carboxylate Chemical compound S1C(NC(C)=O)=NC(CCC=2C=CC(N)=CC=2)=C1C(=O)OCC OBIIWXHXIQXEHF-UHFFFAOYSA-N 0.000 description 2
- NHVZOFMMHWHGKY-UHFFFAOYSA-N ethyl 2-acetamido-4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethyl]-1,3-thiazole-5-carboxylate Chemical compound S1C(NC(C)=O)=NC(CCC=2C=CC(NC(=O)OC(C)(C)C)=CC=2)=C1C(=O)OCC NHVZOFMMHWHGKY-UHFFFAOYSA-N 0.000 description 2
- RJQOJTPJOSHXLD-UHFFFAOYSA-N ethyl 2-acetamido-5-[(3-methylsulfanylphenyl)methyl]-1,3-thiazole-4-carboxylate Chemical compound N1=C(NC(C)=O)SC(CC=2C=C(SC)C=CC=2)=C1C(=O)OCC RJQOJTPJOSHXLD-UHFFFAOYSA-N 0.000 description 2
- YSSDYOSYQQXGBA-UHFFFAOYSA-N ethyl 2-acetamido-5-[(4-methylsulfanylphenyl)methyl]-1,3-thiazole-4-carboxylate Chemical compound N1=C(NC(C)=O)SC(CC=2C=CC(SC)=CC=2)=C1C(=O)OCC YSSDYOSYQQXGBA-UHFFFAOYSA-N 0.000 description 2
- VMFKLNTXKXRZIC-UHFFFAOYSA-N ethyl 2-acetamido-5-benzyl-1,3-thiazole-4-carboxylate Chemical compound N1=C(NC(C)=O)SC(CC=2C=CC=CC=2)=C1C(=O)OCC VMFKLNTXKXRZIC-UHFFFAOYSA-N 0.000 description 2
- YYZWXTGTIZIHCH-UHFFFAOYSA-N ethyl 2-amino-5-[(4-methylsulfanylphenyl)methyl]-1,3-thiazole-4-carboxylate Chemical compound N1=C(N)SC(CC=2C=CC(SC)=CC=2)=C1C(=O)OCC YYZWXTGTIZIHCH-UHFFFAOYSA-N 0.000 description 2
- QEICSUTUPITSQL-UHFFFAOYSA-N ethyl 3-[4-[3-(2-acetamido-1,3-thiazol-4-yl)propyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OCC)=CC=C1CCCC1=CSC(NC(C)=O)=N1 QEICSUTUPITSQL-UHFFFAOYSA-N 0.000 description 2
- CGNJOYUSPNGALU-UHFFFAOYSA-N ethyl 3-bromo-2-oxo-4-phenylbutanoate Chemical compound CCOC(=O)C(=O)C(Br)CC1=CC=CC=C1 CGNJOYUSPNGALU-UHFFFAOYSA-N 0.000 description 2
- IWDKIHJMBNTQIT-UHFFFAOYSA-N ethyl 3-bromo-4-(3-methylsulfanylphenyl)-2-oxobutanoate Chemical compound CCOC(=O)C(=O)C(Br)CC1=CC=CC(SC)=C1 IWDKIHJMBNTQIT-UHFFFAOYSA-N 0.000 description 2
- PUGRQVBMBJKFEQ-UHFFFAOYSA-N ethyl 3-bromo-4-(4-methylsulfanylphenyl)-2-oxobutanoate Chemical compound CCOC(=O)C(=O)C(Br)CC1=CC=C(SC)C=C1 PUGRQVBMBJKFEQ-UHFFFAOYSA-N 0.000 description 2
- XMIVTAOFQJBIGO-UHFFFAOYSA-N ethyl 4-(2-bromoacetyl)benzoate Chemical compound CCOC(=O)C1=CC=C(C(=O)CBr)C=C1 XMIVTAOFQJBIGO-UHFFFAOYSA-N 0.000 description 2
- BBKMEEMVJNOFIZ-UHFFFAOYSA-N ethyl 4-(3-methylsulfanylphenyl)-2-oxobutanoate Chemical compound CCOC(=O)C(=O)CCC1=CC=CC(SC)=C1 BBKMEEMVJNOFIZ-UHFFFAOYSA-N 0.000 description 2
- VUYHRTFKHBIJLA-UHFFFAOYSA-N ethyl 4-(4-methylsulfanylphenyl)-2-oxobutanoate Chemical compound CCOC(=O)C(=O)CCC1=CC=C(SC)C=C1 VUYHRTFKHBIJLA-UHFFFAOYSA-N 0.000 description 2
- FOGLNGQYERMUQC-UHFFFAOYSA-N ethyl 5-[2-[4-(2-acetamido-1,3-thiazol-4-yl)phenyl]ethyl]-1,3-oxazole-4-carboxylate Chemical compound N1=COC(CCC=2C=CC(=CC=2)C=2N=C(NC(C)=O)SC=2)=C1C(=O)OCC FOGLNGQYERMUQC-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- WQRJKUWDNDJFMP-OAQYLSRUSA-N methyl (3r)-1-[[2-acetamido-4-[2-[4-[[n,n'-bis[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]amino]phenyl]ethyl]-1,3-thiazol-5-yl]methyl]pyrrolidine-3-carboxylate Chemical compound C1[C@H](C(=O)OC)CCN1CC1=C(CCC=2C=CC(N\C(NC(=O)OC(C)(C)C)=N\C(=O)OC(C)(C)C)=CC=2)N=C(NC(C)=O)S1 WQRJKUWDNDJFMP-OAQYLSRUSA-N 0.000 description 2
- UMUDJBDRRIBERP-VOTSOKGWSA-N methyl (e)-3-(3-methylsulfanylphenyl)prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=CC(SC)=C1 UMUDJBDRRIBERP-VOTSOKGWSA-N 0.000 description 2
- LBAQELYBSGIOGE-UHFFFAOYSA-N methyl 3-(3-methylsulfanylphenyl)propanoate Chemical compound COC(=O)CCC1=CC=CC(SC)=C1 LBAQELYBSGIOGE-UHFFFAOYSA-N 0.000 description 2
- LXZAFOHXMUDYNN-UHFFFAOYSA-N methyl 3-(4-methylsulfanylphenyl)propanoate Chemical compound COC(=O)CCC1=CC=C(SC)C=C1 LXZAFOHXMUDYNN-UHFFFAOYSA-N 0.000 description 2
- ALIJCZHTMFUTAC-UHFFFAOYSA-N methyl 3-[4-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1C1=C(CC=2C=CC(=CC=2)S(C)(=O)=O)SC(NC(C)=O)=N1 ALIJCZHTMFUTAC-UHFFFAOYSA-N 0.000 description 2
- PPHWOSSGHBGOAO-UHFFFAOYSA-N methyl 4-[3-(2-acetamido-1,3-thiazol-4-yl)propyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCCC1=CSC(NC(C)=O)=N1 PPHWOSSGHBGOAO-UHFFFAOYSA-N 0.000 description 2
- ZQKSUJFPHHRUPA-UHFFFAOYSA-N methyl 4-[3-(2-amino-1,3-thiazol-4-yl)propyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCCC1=CSC(N)=N1 ZQKSUJFPHHRUPA-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- CBTZUXIQRMFBMP-UHFFFAOYSA-N n-[2-[4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl]ethylcarbamothioyl]benzamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCNC(=S)NC(=O)C=3C=CC=CC=3)=CC=2)=C1 CBTZUXIQRMFBMP-UHFFFAOYSA-N 0.000 description 2
- VYFHRANFICFMKR-UHFFFAOYSA-N n-[4-(4-formylphenyl)-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(C=O)=CC=2)=C1CC1=CC=C(S(C)(=O)=O)C=C1 VYFHRANFICFMKR-UHFFFAOYSA-N 0.000 description 2
- NHMFBSLHUHPIAZ-UHFFFAOYSA-N n-[4-(hydroxymethyl)-5-[(3-methylsulfanylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CSC1=CC=CC(CC2=C(N=C(NC(C)=O)S2)CO)=C1 NHMFBSLHUHPIAZ-UHFFFAOYSA-N 0.000 description 2
- DPEJQFUYDGUMRA-ZHACJKMWSA-N n-[4-[(e)-2-[3-[2-[tert-butyl(dimethyl)silyl]oxyethyl]phenyl]ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(\C=C\C=2C=C(CCO[Si](C)(C)C(C)(C)C)C=CC=2)=C1 DPEJQFUYDGUMRA-ZHACJKMWSA-N 0.000 description 2
- LLHXRSQFZYVMSN-ZHACJKMWSA-N n-[4-[(e)-2-[4-[2-(1,3-dioxoisoindol-2-yl)ethyl]phenyl]ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(\C=C\C=2C=CC(CCN3C(C4=CC=CC=C4C3=O)=O)=CC=2)=C1 LLHXRSQFZYVMSN-ZHACJKMWSA-N 0.000 description 2
- IXGOHFGFIQBMQQ-UHFFFAOYSA-N n-[4-[2-(2-amino-1h-benzimidazol-4-yl)ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=3NC(N)=NC=3C=CC=2)=C1 IXGOHFGFIQBMQQ-UHFFFAOYSA-N 0.000 description 2
- WGKPTXHNHFZXRW-UHFFFAOYSA-N n-[4-[2-(4-aminophenyl)ethyl]-5-[(3-methylsulfonylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=1C=CC(S(C)(=O)=O)=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(N)C=C1 WGKPTXHNHFZXRW-UHFFFAOYSA-N 0.000 description 2
- FRRHDFJEENLXOJ-UHFFFAOYSA-N n-[4-[2-(4-aminophenyl)ethyl]-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(N)C=C1 FRRHDFJEENLXOJ-UHFFFAOYSA-N 0.000 description 2
- KLTKALRLRKZQDA-UHFFFAOYSA-N n-[4-[2-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]ethyl]phenyl]-2-aminoacetamide;hydrochloride Chemical compound Cl.C=1C=C(S(C)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(NC(=O)CN)C=C1 KLTKALRLRKZQDA-UHFFFAOYSA-N 0.000 description 2
- SQQOGWCYMYAMID-UHFFFAOYSA-N n-[4-[2-[3-(2-hydroxyethyl)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=C(CCO)C=CC=2)=C1 SQQOGWCYMYAMID-UHFFFAOYSA-N 0.000 description 2
- KHEVOGFILFUFAF-UHFFFAOYSA-N n-[4-[2-[4-(2-aminoethylamino)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide;dihydrochloride Chemical compound Cl.Cl.S1C(NC(=O)C)=NC(CCC=2C=CC(NCCN)=CC=2)=C1 KHEVOGFILFUFAF-UHFFFAOYSA-N 0.000 description 2
- XGBYGTDEQYETNE-UHFFFAOYSA-N n-[4-[2-[4-(3-bromopropyl)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCCBr)=CC=2)=C1 XGBYGTDEQYETNE-UHFFFAOYSA-N 0.000 description 2
- PTPLHVSCNKUOFO-UHFFFAOYSA-N n-[4-[2-[4-(3-hydroxypropyl)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCCO)=CC=2)=C1 PTPLHVSCNKUOFO-UHFFFAOYSA-N 0.000 description 2
- LMDXCMJWFMSUAI-UHFFFAOYSA-N n-[4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(NC(N)=N)=CC=2)=C1 LMDXCMJWFMSUAI-UHFFFAOYSA-N 0.000 description 2
- XOLIYIHOJKFTOB-UHFFFAOYSA-N n-[4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-5-[(3-methylsulfonylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=1C=CC(S(C)(=O)=O)=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(NC(N)=N)C=C1 XOLIYIHOJKFTOB-UHFFFAOYSA-N 0.000 description 2
- JPWHQCKRUFRDOF-UHFFFAOYSA-N n-[4-[2-[4-[2-(1-aminoethylideneamino)ethyl]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(CCNC(=N)C)=CC=C1CCC1=CSC(NC(C)=O)=N1 JPWHQCKRUFRDOF-UHFFFAOYSA-N 0.000 description 2
- GWPPDGBJVUYULN-UHFFFAOYSA-N n-[4-[2-[4-[2-(carbamothioylamino)ethyl]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCNC(N)=S)=CC=2)=C1 GWPPDGBJVUYULN-UHFFFAOYSA-N 0.000 description 2
- XTINWECMQPYZDV-UHFFFAOYSA-N n-[4-[2-[4-[2-(diaminomethylideneamino)ethyl]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCNC(N)=N)=CC=2)=C1 XTINWECMQPYZDV-UHFFFAOYSA-N 0.000 description 2
- XDAZWGADZMRCAV-UHFFFAOYSA-N n-[4-[2-[4-[2-[(n'-methylcarbamimidoyl)amino]ethyl]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(CCNC(=N)NC)=CC=C1CCC1=CSC(NC(C)=O)=N1 XDAZWGADZMRCAV-UHFFFAOYSA-N 0.000 description 2
- CPSQTCDIIHOYDR-UHFFFAOYSA-N n-[4-[2-[4-[3-(1,3-dioxoisoindol-2-yl)propyl]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCCN3C(C4=CC=CC=C4C3=O)=O)=CC=2)=C1 CPSQTCDIIHOYDR-UHFFFAOYSA-N 0.000 description 2
- JNUOEPYKTPVUBR-UHFFFAOYSA-N n-[4-[3-(4-formylphenyl)propyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(C=O)=CC=2)=C1 JNUOEPYKTPVUBR-UHFFFAOYSA-N 0.000 description 2
- GNWMBYWIKSQSNZ-UHFFFAOYSA-N n-[4-[3-[4-(chloromethyl)phenyl]propyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(CCl)=CC=2)=C1 GNWMBYWIKSQSNZ-UHFFFAOYSA-N 0.000 description 2
- ZKSHLSWJAMNLHH-UHFFFAOYSA-N n-[4-[3-[4-(hydroxymethyl)phenyl]propyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(CO)=CC=2)=C1 ZKSHLSWJAMNLHH-UHFFFAOYSA-N 0.000 description 2
- HHTWHADIVNZBHI-UHFFFAOYSA-N n-[4-[3-[4-[2-(diaminomethylideneamino)ethyl]phenyl]propyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(CCNC(N)=N)=CC=2)=C1 HHTWHADIVNZBHI-UHFFFAOYSA-N 0.000 description 2
- RSBGDGMRVWBANL-UHFFFAOYSA-N n-[4-[4-(hydroxymethyl)phenyl]-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CO)=CC=2)=C1CC1=CC=C(S(C)(=O)=O)C=C1 RSBGDGMRVWBANL-UHFFFAOYSA-N 0.000 description 2
- IMDNMSJSKSJFHH-UHFFFAOYSA-N n-[4-formyl-5-[(3-methylsulfanylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound CSC1=CC=CC(CC2=C(N=C(NC(C)=O)S2)C=O)=C1 IMDNMSJSKSJFHH-UHFFFAOYSA-N 0.000 description 2
- XJUAHQKXVLOATH-DHZHZOJOSA-N n-[5-[(3-methylsulfanylphenyl)methyl]-4-[(e)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound CSC1=CC=CC(CC2=C(N=C(NC(C)=O)S2)\C=C\C=2C=CC(=CC=2)[N+]([O-])=O)=C1 XJUAHQKXVLOATH-DHZHZOJOSA-N 0.000 description 2
- XJUAHQKXVLOATH-FLIBITNWSA-N n-[5-[(3-methylsulfanylphenyl)methyl]-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound CSC1=CC=CC(CC2=C(N=C(NC(C)=O)S2)\C=C/C=2C=CC(=CC=2)[N+]([O-])=O)=C1 XJUAHQKXVLOATH-FLIBITNWSA-N 0.000 description 2
- VIIJHRKLEMOMDR-FLIBITNWSA-N n-[5-[(3-methylsulfonylphenyl)methyl]-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=1C=CC(S(C)(=O)=O)=CC=1CC=1SC(NC(=O)C)=NC=1\C=C/C1=CC=C([N+]([O-])=O)C=C1 VIIJHRKLEMOMDR-FLIBITNWSA-N 0.000 description 2
- PUJFOYARJJKCHV-KPKJPENVSA-N n-[5-[(4-methylsulfanylphenyl)methyl]-4-[(e)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(SC)=CC=C1CC1=C(\C=C\C=2C=CC(=CC=2)[N+]([O-])=O)N=C(NC(C)=O)S1 PUJFOYARJJKCHV-KPKJPENVSA-N 0.000 description 2
- KQTXPUPEWYNVFD-KPKJPENVSA-N n-[5-[(4-methylsulfonylphenyl)methyl]-4-[(e)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 KQTXPUPEWYNVFD-KPKJPENVSA-N 0.000 description 2
- KQTXPUPEWYNVFD-GHXNOFRVSA-N n-[5-[(4-methylsulfonylphenyl)methyl]-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1\C=C/C1=CC=C([N+]([O-])=O)C=C1 KQTXPUPEWYNVFD-GHXNOFRVSA-N 0.000 description 2
- ZYVKXCQNEOXSJV-MLPAPPSSSA-N n-[[2-acetamido-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-5-yl]methyl]-n-methyl-4-methylsulfonylbenzamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(=O)N(C)CC=1SC(NC(C)=O)=NC=1\C=C/C1=CC=C([N+]([O-])=O)C=C1 ZYVKXCQNEOXSJV-MLPAPPSSSA-N 0.000 description 2
- PJJUOFWGZQGWAX-UHFFFAOYSA-N n-[[2-acetamido-4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-5-yl]methyl]-n-methyl-4-methylsulfonylbenzamide Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(=O)N(C)CC=1SC(NC(C)=O)=NC=1CCC1=CC=C(N)C=C1 PJJUOFWGZQGWAX-UHFFFAOYSA-N 0.000 description 2
- OLUVHIOXLODFLH-UHFFFAOYSA-N n-methoxy-n-methyl-3-methylsulfanylbenzamide Chemical compound CON(C)C(=O)C1=CC=CC(SC)=C1 OLUVHIOXLODFLH-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 150000003349 semicarbazides Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FLLXSNQKWDHDAH-UHFFFAOYSA-N tert-butyl N-[[4-[2-[2-acetamido-5-[(3-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]ethyl]anilino]-[(2-methylpropan-2-yl)oxycarbonylamino]methyl]carbamate Chemical compound C=1C=CC(S(C)(=O)=O)=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(NC(NC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)C=C1 FLLXSNQKWDHDAH-UHFFFAOYSA-N 0.000 description 2
- BHRXLIXWHOCBQN-UHFFFAOYSA-N tert-butyl n-[2-[4-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]phenyl]ethyl]carbamate Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CCNC(=O)OC(C)(C)C)=CC=2)=C1CC1=CC=C(S(C)(=O)=O)C=C1 BHRXLIXWHOCBQN-UHFFFAOYSA-N 0.000 description 2
- ZEANFNXLPLAOMF-UHFFFAOYSA-N tert-butyl n-[4-[2-(2-acetamido-5-formyl-1,3-thiazol-4-yl)ethyl]phenyl]carbamate Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(NC(=O)OC(C)(C)C)=CC=2)=C1C=O ZEANFNXLPLAOMF-UHFFFAOYSA-N 0.000 description 2
- GJNAXBRGDUUEMT-UHFFFAOYSA-N tert-butyl n-[4-[4-(2-acetamido-1,3-thiazol-4-yl)phenyl]-2-oxobutyl]carbamate Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CCC(=O)CNC(=O)OC(C)(C)C)=CC=2)=C1 GJNAXBRGDUUEMT-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- YMFMWVKKIBKMGW-GGMCWBHBSA-N (3r)-1-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n,n-dimethylpyrrolidine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1[C@H](C(=O)N(C)C)CCN1CC1=C(CCC=2C=CC(NC(N)=N)=CC=2)N=C(NC(C)=O)S1 YMFMWVKKIBKMGW-GGMCWBHBSA-N 0.000 description 1
- LWBGWZLUJJPRLQ-QCUBGVIVSA-N (3r)-1-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n-methylpyrrolidine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1[C@H](C(=O)NC)CCN1CC1=C(CCC=2C=CC(NC(N)=N)=CC=2)N=C(NC(C)=O)S1 LWBGWZLUJJPRLQ-QCUBGVIVSA-N 0.000 description 1
- APLHVNUAUYDXFB-HXUWFJFHSA-N (3r)-1-[[2-acetamido-4-[2-[4-[[n,n'-bis[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]amino]phenyl]ethyl]-1,3-thiazol-5-yl]methyl]pyrrolidine-3-carboxylic acid Chemical compound C([C@@H](CC1)C(O)=O)N1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(N\C(NC(=O)OC(C)(C)C)=N\C(=O)OC(C)(C)C)C=C1 APLHVNUAUYDXFB-HXUWFJFHSA-N 0.000 description 1
- YMFMWVKKIBKMGW-SQKCAUCHSA-N (3s)-1-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n,n-dimethylpyrrolidine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](C(=O)N(C)C)CCN1CC1=C(CCC=2C=CC(NC(N)=N)=CC=2)N=C(NC(C)=O)S1 YMFMWVKKIBKMGW-SQKCAUCHSA-N 0.000 description 1
- LWBGWZLUJJPRLQ-CKUXDGONSA-N (3s)-1-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n-methylpyrrolidine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1[C@@H](C(=O)NC)CCN1CC1=C(CCC=2C=CC(NC(N)=N)=CC=2)N=C(NC(C)=O)S1 LWBGWZLUJJPRLQ-CKUXDGONSA-N 0.000 description 1
- APLHVNUAUYDXFB-FQEVSTJZSA-N (3s)-1-[[2-acetamido-4-[2-[4-[[(z)-n,n'-bis[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]amino]phenyl]ethyl]-1,3-thiazol-5-yl]methyl]pyrrolidine-3-carboxylic acid Chemical compound C([C@H](CC1)C(O)=O)N1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(N\C(NC(=O)OC(C)(C)C)=N\C(=O)OC(C)(C)C)C=C1 APLHVNUAUYDXFB-FQEVSTJZSA-N 0.000 description 1
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- WLNABZSWPDWUFJ-ASTDGNLGSA-N (e)-3-[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]-n,n-dimethylprop-2-enamide;hydrochloride Chemical compound Cl.S1C(NC(C)=O)=NC(CCC=2C=CC(NC(N)=N)=CC=2)=C1/C=C/C(=O)N(C)C WLNABZSWPDWUFJ-ASTDGNLGSA-N 0.000 description 1
- FCKDTJOJIUHOBD-CCEZHUSRSA-N (e)-3-[2-acetamido-4-[2-[4-[[n,n'-bis[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]amino]phenyl]ethyl]-1,3-thiazol-5-yl]prop-2-enoic acid Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(N\C(NC(=O)OC(C)(C)C)=N\C(=O)OC(C)(C)C)=CC=2)=C1\C=C\C(O)=O FCKDTJOJIUHOBD-CCEZHUSRSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- WCOCCXZFEJGHTC-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(CBr)C=C1 WCOCCXZFEJGHTC-UHFFFAOYSA-N 0.000 description 1
- CKHDZRSJBJRENL-XFXZXTDPSA-N 2-[4-[(Z)-2-[2-acetamido-5-[(4-methylsulfanylphenyl)methyl]-1,3-thiazol-4-yl]ethenyl]phenyl]acetic acid Chemical compound C1=CC(SC)=CC=C1CC1=C(\C=C/C=2C=CC(CC(O)=O)=CC=2)N=C(NC(C)=O)S1 CKHDZRSJBJRENL-XFXZXTDPSA-N 0.000 description 1
- VOUIKXJMPKEJLI-VOTSOKGWSA-N 2-[4-[(e)-2-(2-acetamido-1,3-thiazol-4-yl)ethenyl]phenyl]acetic acid Chemical compound S1C(NC(=O)C)=NC(\C=C\C=2C=CC(CC(O)=O)=CC=2)=C1 VOUIKXJMPKEJLI-VOTSOKGWSA-N 0.000 description 1
- CKHDZRSJBJRENL-FMIVXFBMSA-N 2-[4-[(e)-2-[2-acetamido-5-[(4-methylsulfanylphenyl)methyl]-1,3-thiazol-4-yl]ethenyl]phenyl]acetic acid Chemical compound C1=CC(SC)=CC=C1CC1=C(\C=C\C=2C=CC(CC(O)=O)=CC=2)N=C(NC(C)=O)S1 CKHDZRSJBJRENL-FMIVXFBMSA-N 0.000 description 1
- VOUIKXJMPKEJLI-SREVYHEPSA-N 2-[4-[(z)-2-(2-acetamido-1,3-thiazol-4-yl)ethenyl]phenyl]acetic acid Chemical compound S1C(NC(=O)C)=NC(\C=C/C=2C=CC(CC(O)=O)=CC=2)=C1 VOUIKXJMPKEJLI-SREVYHEPSA-N 0.000 description 1
- IQESBDXBOMJXLY-UHFFFAOYSA-N 2-acetamido-4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethyl]-1,3-thiazole-5-carboxylic acid Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(NC(=O)OC(C)(C)C)=CC=2)=C1C(O)=O IQESBDXBOMJXLY-UHFFFAOYSA-N 0.000 description 1
- SYZRZLUNWVNNNV-UHFFFAOYSA-N 2-bromoacetyl chloride Chemical compound ClC(=O)CBr SYZRZLUNWVNNNV-UHFFFAOYSA-N 0.000 description 1
- QFGRBBWYHIYNIB-UHFFFAOYSA-N 2-methylsulfanyl-4,5-dihydro-1,3-thiazole Chemical compound CSC1=NCCS1 QFGRBBWYHIYNIB-UHFFFAOYSA-N 0.000 description 1
- KWPQTFXULUUCGD-UHFFFAOYSA-N 3,4,5,7,8,9,10,10a-octahydropyrido[1,2-a][1,4]diazepine Chemical compound C1CCN=CC2CCCCN21 KWPQTFXULUUCGD-UHFFFAOYSA-N 0.000 description 1
- YQWPHBFLHAJVCG-UHFFFAOYSA-N 3-(4-sulfanylphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(S)C=C1 YQWPHBFLHAJVCG-UHFFFAOYSA-N 0.000 description 1
- FINXEMRTHMEPCJ-UHFFFAOYSA-N 3-[2-[tert-butyl(dimethyl)silyl]oxyethyl]benzaldehyde Chemical compound CC(C)(C)[Si](C)(C)OCCC1=CC=CC(C=O)=C1 FINXEMRTHMEPCJ-UHFFFAOYSA-N 0.000 description 1
- UWOMODUPJXNTIR-UHFFFAOYSA-N 3-[4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl]-n-(diaminomethylidene)propanamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCC(=O)NC(N)=N)=CC=2)=C1 UWOMODUPJXNTIR-UHFFFAOYSA-N 0.000 description 1
- NVPDTKVNSCRNOE-UHFFFAOYSA-N 3-[4-[3-(2-acetamido-1,3-thiazol-4-yl)propyl]phenyl]propanoic acid Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(CCC(O)=O)=CC=2)=C1 NVPDTKVNSCRNOE-UHFFFAOYSA-N 0.000 description 1
- JGSIAOZAXBWRFO-UHFFFAOYSA-N 3-methylsulfanyl-1-phenyl-4,5-dihydrobenzo[g]indazole Chemical compound C1CC2=CC=CC=C2C2=C1C(SC)=NN2C1=CC=CC=C1 JGSIAOZAXBWRFO-UHFFFAOYSA-N 0.000 description 1
- PZGADOOBMVLBJE-UHFFFAOYSA-N 3-methylsulfanylbenzoic acid Chemical compound CSC1=CC=CC(C(O)=O)=C1 PZGADOOBMVLBJE-UHFFFAOYSA-N 0.000 description 1
- WJEZEUJKYFXNKJ-UHFFFAOYSA-N 4-(2-bromoethyl)benzaldehyde Chemical compound BrCCC1=CC=C(C=O)C=C1 WJEZEUJKYFXNKJ-UHFFFAOYSA-N 0.000 description 1
- NFFHFVNSUZBUGM-UHFFFAOYSA-N 4-[4-(2-amino-1,3-thiazol-4-yl)phenyl]butyl 2,2-dimethylpropanoate Chemical compound C1=CC(CCCCOC(=O)C(C)(C)C)=CC=C1C1=CSC(N)=N1 NFFHFVNSUZBUGM-UHFFFAOYSA-N 0.000 description 1
- QWFPOHNPLNOMJD-UHFFFAOYSA-N 4-[4-(2-bromoacetyl)phenyl]butyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCCCC1=CC=C(C(=O)CBr)C=C1 QWFPOHNPLNOMJD-UHFFFAOYSA-N 0.000 description 1
- QRVYABWJVXXOTN-UHFFFAOYSA-N 4-methylsulfanylbenzaldehyde Chemical compound CSC1=CC=C(C=O)C=C1 QRVYABWJVXXOTN-UHFFFAOYSA-N 0.000 description 1
- AJBWNNKDUMXZLM-UHFFFAOYSA-N 4-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=C(C(O)=O)C=C1 AJBWNNKDUMXZLM-UHFFFAOYSA-N 0.000 description 1
- STGGFMRQIUCHDG-AUWJEWJLSA-N 4-n-[[2-acetamido-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-5-yl]methyl]-1-n,1-n,4-n-trimethylbenzene-1,4-dicarboxamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C(=O)N(C)CC1=C(\C=C/C=2C=CC(=CC=2)[N+]([O-])=O)N=C(NC(C)=O)S1 STGGFMRQIUCHDG-AUWJEWJLSA-N 0.000 description 1
- KACBNDOFAUCVDY-UHFFFAOYSA-N 4-n-[[2-acetamido-4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-5-yl]methyl]-1-n,1-n,4-n-trimethylbenzene-1,4-dicarboxamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C(=O)N(C)CC1=C(CCC=2C=CC(N)=CC=2)N=C(NC(C)=O)S1 KACBNDOFAUCVDY-UHFFFAOYSA-N 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- LDZLXQFDGRCELX-UHFFFAOYSA-N 4-phenylbutan-1-ol Chemical compound OCCCCC1=CC=CC=C1 LDZLXQFDGRCELX-UHFFFAOYSA-N 0.000 description 1
- ZURFBFHBRXNQEH-UHFFFAOYSA-N 4-phenylbutyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCCCC1=CC=CC=C1 ZURFBFHBRXNQEH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- JAGZUIGGHGTFHO-UHFFFAOYSA-N Ethyl 3-phenylpropanoate Chemical compound CCOC(=O)CCC1=CC=CC=C1 JAGZUIGGHGTFHO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150012983 VAP-1 gene Proteins 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- LVZMHZFYTMOQCY-RMKNXTFCSA-N ethyl 2-acetamido-4-[(e)-2-(4-nitrophenyl)ethenyl]-1,3-thiazole-5-carboxylate Chemical compound S1C(NC(C)=O)=NC(\C=C\C=2C=CC(=CC=2)[N+]([O-])=O)=C1C(=O)OCC LVZMHZFYTMOQCY-RMKNXTFCSA-N 0.000 description 1
- YUOWKODCPZVMMU-UHFFFAOYSA-N ethyl 2-amino-5-[(3-methylsulfanylphenyl)methyl]-1,3-thiazole-4-carboxylate Chemical compound N1=C(N)SC(CC=2C=C(SC)C=CC=2)=C1C(=O)OCC YUOWKODCPZVMMU-UHFFFAOYSA-N 0.000 description 1
- OHAMQMFWKYSVPF-UHFFFAOYSA-N ethyl 2-amino-5-benzyl-1,3-thiazole-4-carboxylate Chemical compound N1=C(N)SC(CC=2C=CC=CC=2)=C1C(=O)OCC OHAMQMFWKYSVPF-UHFFFAOYSA-N 0.000 description 1
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 1
- FVRAVWDGBOBLHP-UHFFFAOYSA-N ethyl 2-methylsulfanyl-4,5-dihydroimidazole-1-carboxylate Chemical compound CCOC(=O)N1CCN=C1SC FVRAVWDGBOBLHP-UHFFFAOYSA-N 0.000 description 1
- STPXIOGYOLJXMZ-UHFFFAOYSA-N ethyl 2-oxo-4-phenylbutanoate Chemical compound CCOC(=O)C(=O)CCC1=CC=CC=C1 STPXIOGYOLJXMZ-UHFFFAOYSA-N 0.000 description 1
- XXFFFMAOWGKEAA-UHFFFAOYSA-N ethyl 3-[4-(2-amino-1,3-thiazol-4-yl)phenyl]propanoate Chemical compound C1=CC(CCC(=O)OCC)=CC=C1C1=CSC(N)=N1 XXFFFMAOWGKEAA-UHFFFAOYSA-N 0.000 description 1
- DVZXWRRQCWDVOS-UHFFFAOYSA-N ethyl 3-[4-(2-bromoacetyl)phenyl]propanoate Chemical compound CCOC(=O)CCC1=CC=C(C(=O)CBr)C=C1 DVZXWRRQCWDVOS-UHFFFAOYSA-N 0.000 description 1
- JZFHXSLGZXCBPH-UHFFFAOYSA-N ethyl 4-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=C(CC=2C=CC(=CC=2)S(C)(=O)=O)SC(NC(C)=O)=N1 JZFHXSLGZXCBPH-UHFFFAOYSA-N 0.000 description 1
- IMPLMBNPKXVMRW-UHFFFAOYSA-N ethyl 4-[2-amino-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=C(CC=2C=CC(=CC=2)S(C)(=O)=O)SC(N)=N1 IMPLMBNPKXVMRW-UHFFFAOYSA-N 0.000 description 1
- LCZNRTUMNCLBAN-UHFFFAOYSA-N ethyl 4-[2-bromo-3-(4-methylsulfonylphenyl)propanoyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C(=O)C(Br)CC1=CC=C(S(C)(=O)=O)C=C1 LCZNRTUMNCLBAN-UHFFFAOYSA-N 0.000 description 1
- BZTAGXNLKARSQT-UHFFFAOYSA-N ethyl 4-[3-(4-methylsulfonylphenyl)propanoyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C(=O)CCC1=CC=C(S(C)(=O)=O)C=C1 BZTAGXNLKARSQT-UHFFFAOYSA-N 0.000 description 1
- GLOAPLPTWAXAIG-UHFFFAOYSA-N ethyl 4-acetylbenzoate Chemical compound CCOC(=O)C1=CC=C(C(C)=O)C=C1 GLOAPLPTWAXAIG-UHFFFAOYSA-N 0.000 description 1
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- VWEABJBFBMDTES-GTBONMDNSA-N methyl (3r)-1-[[2-acetamido-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-5-yl]methyl]pyrrolidine-3-carboxylate Chemical compound C1[C@H](C(=O)OC)CCN1CC1=C(\C=C/C=2C=CC(=CC=2)[N+]([O-])=O)N=C(NC(C)=O)S1 VWEABJBFBMDTES-GTBONMDNSA-N 0.000 description 1
- VVBSXSVVMNGQIN-NUBCRITNSA-N methyl (3r)-pyrrolidine-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@@H]1CCNC1 VVBSXSVVMNGQIN-NUBCRITNSA-N 0.000 description 1
- WQRJKUWDNDJFMP-NRFANRHFSA-N methyl (3s)-1-[[2-acetamido-4-[2-[4-[[(z)-n,n'-bis[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]amino]phenyl]ethyl]-1,3-thiazol-5-yl]methyl]pyrrolidine-3-carboxylate Chemical compound C1[C@@H](C(=O)OC)CCN1CC1=C(CCC=2C=CC(N\C(NC(=O)OC(C)(C)C)=N\C(=O)OC(C)(C)C)=CC=2)N=C(NC(C)=O)S1 WQRJKUWDNDJFMP-NRFANRHFSA-N 0.000 description 1
- KVXMLLMZXPRPNG-VOTSOKGWSA-N methyl (e)-3-(4-formylphenyl)prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=C(C=O)C=C1 KVXMLLMZXPRPNG-VOTSOKGWSA-N 0.000 description 1
- DMMKZSCNXOYYSV-FIFLTTCUSA-N methyl (e)-3-[4-[(e)-2-(2-acetamido-1,3-thiazol-4-yl)ethenyl]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OC)=CC=C1\C=C\C1=CSC(NC(C)=O)=N1 DMMKZSCNXOYYSV-FIFLTTCUSA-N 0.000 description 1
- AIGYEFZBLWJHCP-MDWZMJQESA-N methyl (e)-3-[4-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]phenyl]prop-2-enoate Chemical compound C1=CC(/C=C/C(=O)OC)=CC=C1C1=C(CC=2C=CC(=CC=2)S(C)(=O)=O)SC(NC(C)=O)=N1 AIGYEFZBLWJHCP-MDWZMJQESA-N 0.000 description 1
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 1
- PCANUTXUTRHVTG-UHFFFAOYSA-N methyl 4-(4-oxopentyl)benzoate Chemical compound COC(=O)C1=CC=C(CCCC(C)=O)C=C1 PCANUTXUTRHVTG-UHFFFAOYSA-N 0.000 description 1
- XGGZCCXXVUWCQN-UHFFFAOYSA-N methyl ethanimidothioate;hydroiodide Chemical compound I.CSC(C)=N XGGZCCXXVUWCQN-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- LQZUREXKKWCTNL-UHFFFAOYSA-N n-(5-benzyl-4-formyl-1,3-thiazol-2-yl)acetamide Chemical compound S1C(NC(=O)C)=NC(C=O)=C1CC1=CC=CC=C1 LQZUREXKKWCTNL-UHFFFAOYSA-N 0.000 description 1
- NBUKMHXINQOFDI-UHFFFAOYSA-N n-[4-(chloromethyl)-1,3-thiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC(CCl)=CS1 NBUKMHXINQOFDI-UHFFFAOYSA-N 0.000 description 1
- SWZYYOSOBAVUOB-AATRIKPKSA-N n-[4-[(e)-2-[3-(2-hydroxyethyl)phenyl]ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(\C=C\C=2C=C(CCO)C=CC=2)=C1 SWZYYOSOBAVUOB-AATRIKPKSA-N 0.000 description 1
- CULLNADCNVLINP-WAYWQWQTSA-N n-[4-[(z)-2-(2,3-dinitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(\C=C/C=2C(=C(C=CC=2)[N+]([O-])=O)[N+]([O-])=O)=C1 CULLNADCNVLINP-WAYWQWQTSA-N 0.000 description 1
- PZUQPWOBRNFLNX-UHFFFAOYSA-N n-[4-[2-(2,3-diaminophenyl)ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C(=C(N)C=CC=2)N)=C1 PZUQPWOBRNFLNX-UHFFFAOYSA-N 0.000 description 1
- GSKAPZOHKXIOLY-UHFFFAOYSA-N n-[4-[2-(4-aminophenyl)ethyl]-5-[(4-sulfamoylphenyl)methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=1C=C(S(N)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(N)C=C1 GSKAPZOHKXIOLY-UHFFFAOYSA-N 0.000 description 1
- QPXFHMSPBKYZQC-UHFFFAOYSA-N n-[4-[2-(4-aminophenyl)ethyl]-5-[[4-(dimethylsulfamoyl)phenyl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1CC1=C(CCC=2C=CC(N)=CC=2)N=C(NC(C)=O)S1 QPXFHMSPBKYZQC-UHFFFAOYSA-N 0.000 description 1
- SGKXYOFDZACLPC-UHFFFAOYSA-N n-[4-[2-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]ethyl]phenyl]-2-(diaminomethylideneamino)acetamide;hydrochloride Chemical compound Cl.C=1C=C(S(C)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(NC(=O)CNC(N)=N)C=C1 SGKXYOFDZACLPC-UHFFFAOYSA-N 0.000 description 1
- SNRYAJJDVYPVKU-UHFFFAOYSA-N n-[4-[2-[3-(2-aminoethyl)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=C(CCN)C=CC=2)=C1 SNRYAJJDVYPVKU-UHFFFAOYSA-N 0.000 description 1
- VQKLZKRVBIYHGT-UHFFFAOYSA-N n-[4-[2-[3-[2-(1,3-dioxoisoindol-2-yl)ethyl]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=C(CCN3C(C4=CC=CC=C4C3=O)=O)C=CC=2)=C1 VQKLZKRVBIYHGT-UHFFFAOYSA-N 0.000 description 1
- UEFMDQMJTSJUET-UHFFFAOYSA-N n-[4-[2-[4-(3-aminopropyl)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCCN)=CC=2)=C1 UEFMDQMJTSJUET-UHFFFAOYSA-N 0.000 description 1
- SWROQLKQUYQHOP-UHFFFAOYSA-N n-[4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-5-[(4-sulfamoylphenyl)methyl]-1,3-thiazol-2-yl]acetamide;hydrochloride Chemical compound Cl.C=1C=C(S(N)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(NC(N)=N)C=C1 SWROQLKQUYQHOP-UHFFFAOYSA-N 0.000 description 1
- YUPZGEYJHYOBRQ-UHFFFAOYSA-N n-[4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-5-[[4-(dimethylsulfamoyl)phenyl]methyl]-1,3-thiazol-2-yl]acetamide;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)N(C)C)=CC=C1CC1=C(CCC=2C=CC(NC(N)=N)=CC=2)N=C(NC(C)=O)S1 YUPZGEYJHYOBRQ-UHFFFAOYSA-N 0.000 description 1
- GCPNVGOVCAJUSU-UHFFFAOYSA-N n-[4-[2-[4-[2-(1,3-dioxoisoindol-2-yl)ethyl]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCN3C(C4=CC=CC=C4C3=O)=O)=CC=2)=C1 GCPNVGOVCAJUSU-UHFFFAOYSA-N 0.000 description 1
- CNLBDWXYNZYJQZ-UHFFFAOYSA-N n-[4-[2-[4-[2-(4,5-dihydro-1,3-thiazol-2-ylamino)ethyl]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCNC=3SCCN=3)=CC=2)=C1 CNLBDWXYNZYJQZ-UHFFFAOYSA-N 0.000 description 1
- ULOJKBVMGWBDLM-UHFFFAOYSA-N n-[4-[2-[4-[2-(4,5-dihydro-1h-imidazol-2-ylamino)ethyl]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(CCNC=3NCCN=3)=CC=2)=C1 ULOJKBVMGWBDLM-UHFFFAOYSA-N 0.000 description 1
- GOVMSEAGZBTEOC-UHFFFAOYSA-N n-[4-[2-[4-[2-(diaminomethylideneamino)ethylamino]phenyl]ethyl]-1,3-thiazol-2-yl]acetamide;dihydrochloride Chemical compound Cl.Cl.S1C(NC(=O)C)=NC(CCC=2C=CC(NCCNC(N)=N)=CC=2)=C1 GOVMSEAGZBTEOC-UHFFFAOYSA-N 0.000 description 1
- RGRVSXFRDSDUFA-UHFFFAOYSA-N n-[4-[3-(4-aminophenyl)propyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(N)=CC=2)=C1 RGRVSXFRDSDUFA-UHFFFAOYSA-N 0.000 description 1
- NOYWQQBKRKVNBE-UHFFFAOYSA-N n-[4-[3-(4-nitrophenyl)propyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(=CC=2)[N+]([O-])=O)=C1 NOYWQQBKRKVNBE-UHFFFAOYSA-N 0.000 description 1
- RYNIDABXXVOMKB-UHFFFAOYSA-N n-[4-[3-[4-(aminomethyl)phenyl]propyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(CN)=CC=2)=C1 RYNIDABXXVOMKB-UHFFFAOYSA-N 0.000 description 1
- RCPSSICXBRYVBR-UHFFFAOYSA-N n-[4-[3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]propyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(CN3C(C4=CC=CC=C4C3=O)=O)=CC=2)=C1 RCPSSICXBRYVBR-UHFFFAOYSA-N 0.000 description 1
- FHNVNNSGEXDPLB-UHFFFAOYSA-N n-[4-[3-[4-[(diaminomethylideneamino)methyl]phenyl]propyl]-1,3-thiazol-2-yl]acetamide;hydrochloride Chemical compound Cl.S1C(NC(=O)C)=NC(CCCC=2C=CC(CNC(N)=N)=CC=2)=C1 FHNVNNSGEXDPLB-UHFFFAOYSA-N 0.000 description 1
- KGTULMSYLNFBGX-UHFFFAOYSA-N n-[4-[4-(4-amino-3-oxobutyl)phenyl]-1,3-thiazol-2-yl]acetamide;hydrochloride Chemical compound Cl.S1C(NC(=O)C)=NC(C=2C=CC(CCC(=O)CN)=CC=2)=C1 KGTULMSYLNFBGX-UHFFFAOYSA-N 0.000 description 1
- JODRRKBJXYSPLJ-UHFFFAOYSA-N n-[4-[4-(4-aminobutyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CCCCN)=CC=2)=C1 JODRRKBJXYSPLJ-UHFFFAOYSA-N 0.000 description 1
- YCXWJTNDKOVLPE-UHFFFAOYSA-N n-[4-[4-(4-bromobutyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CCCCBr)=CC=2)=C1 YCXWJTNDKOVLPE-UHFFFAOYSA-N 0.000 description 1
- KSWUCJMVOUAKRA-UHFFFAOYSA-N n-[4-[4-(4-hydroxybutyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(C=2C=CC(CCCCO)=CC=2)=C1 KSWUCJMVOUAKRA-UHFFFAOYSA-N 0.000 description 1
- UWLWUNMBJFVQHV-UHFFFAOYSA-N n-[4-[4-[2-(diaminomethylideneamino)ethyl]phenyl]-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-2-yl]acetamide;hydrochloride Chemical compound Cl.S1C(NC(=O)C)=NC(C=2C=CC(CCNC(N)=N)=CC=2)=C1CC1=CC=C(S(C)(=O)=O)C=C1 UWLWUNMBJFVQHV-UHFFFAOYSA-N 0.000 description 1
- FVDYUMVKUQENMA-UHFFFAOYSA-N n-[4-[4-[4-(diaminomethylideneamino)-3-oxobutyl]phenyl]-1,3-thiazol-2-yl]acetamide;hydrochloride Chemical compound Cl.S1C(NC(=O)C)=NC(C=2C=CC(CCC(=O)CNC(N)=N)=CC=2)=C1 FVDYUMVKUQENMA-UHFFFAOYSA-N 0.000 description 1
- DTFMMEYJQVPJOH-UHFFFAOYSA-N n-[4-[4-[4-(diaminomethylideneamino)butyl]phenyl]-1,3-thiazol-2-yl]acetamide;hydrochloride Chemical compound Cl.S1C(NC(=O)C)=NC(C=2C=CC(CCCCNC(N)=N)=CC=2)=C1 DTFMMEYJQVPJOH-UHFFFAOYSA-N 0.000 description 1
- PUJFOYARJJKCHV-GHXNOFRVSA-N n-[5-[(4-methylsulfanylphenyl)methyl]-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C1=CC(SC)=CC=C1CC1=C(\C=C/C=2C=CC(=CC=2)[N+]([O-])=O)N=C(NC(C)=O)S1 PUJFOYARJJKCHV-GHXNOFRVSA-N 0.000 description 1
- IXYKSNYAVMIVTB-XFXZXTDPSA-N n-[5-benzyl-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl]acetamide Chemical compound C=1C=CC=CC=1CC=1SC(NC(=O)C)=NC=1\C=C/C1=CC=C([N+]([O-])=O)C=C1 IXYKSNYAVMIVTB-XFXZXTDPSA-N 0.000 description 1
- AOXOJYOEHPDDJM-MLPAPPSSSA-N n-[[2-acetamido-4-[(z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-5-yl]methyl]-4-acetyl-n-methylbenzamide Chemical compound C=1C=C(C(C)=O)C=CC=1C(=O)N(C)CC=1SC(NC(C)=O)=NC=1\C=C/C1=CC=C([N+]([O-])=O)C=C1 AOXOJYOEHPDDJM-MLPAPPSSSA-N 0.000 description 1
- JWLWUAQSYZNMPV-UHFFFAOYSA-N n-[[2-acetamido-4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-5-yl]methyl]-4-acetyl-n-methylbenzamide Chemical compound C=1C=C(C(C)=O)C=CC=1C(=O)N(C)CC=1SC(NC(C)=O)=NC=1CCC1=CC=C(N)C=C1 JWLWUAQSYZNMPV-UHFFFAOYSA-N 0.000 description 1
- AKFVSGBFOHWAJC-UHFFFAOYSA-N n-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n-methyl-4-methylsulfonylbenzamide;hydrochloride Chemical compound Cl.C=1C=C(S(C)(=O)=O)C=CC=1C(=O)N(C)CC=1SC(NC(C)=O)=NC=1CCC1=CC=C(NC(N)=N)C=C1 AKFVSGBFOHWAJC-UHFFFAOYSA-N 0.000 description 1
- FTFBWRTVDLIRDF-UHFFFAOYSA-N n-[[2-acetamido-4-[2-[4-(diaminomethylideneamino)phenyl]ethyl]-1,3-thiazol-5-yl]methyl]-n-methyl-4-nitrobenzamide;hydrochloride Chemical compound Cl.C=1C=C([N+]([O-])=O)C=CC=1C(=O)N(C)CC=1SC(NC(C)=O)=NC=1CCC1=CC=C(NC(N)=N)C=C1 FTFBWRTVDLIRDF-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical class CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- KUCOHFSKRZZVRO-UHFFFAOYSA-N terephthalaldehyde Chemical compound O=CC1=CC=C(C=O)C=C1 KUCOHFSKRZZVRO-UHFFFAOYSA-N 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- VIFKKSQZPGADPB-UHFFFAOYSA-N tert-butyl N-[[2-[4-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]phenyl]ethylamino]-[(2-methylpropan-2-yl)oxycarbonylamino]methyl]carbamate Chemical compound CC(=O)Nc1nc(c(Cc2ccc(cc2)S(C)(=O)=O)s1)-c1ccc(CCNC(NC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)cc1 VIFKKSQZPGADPB-UHFFFAOYSA-N 0.000 description 1
- NRZYYKACXDZFRF-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O.CC(C)(C)OC(N)=O NRZYYKACXDZFRF-UHFFFAOYSA-N 0.000 description 1
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 1
- NQXOWXNWMRRJAC-UHFFFAOYSA-N tert-butyl n-[2-[4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]anilino]ethyl]carbamate Chemical compound S1C(NC(=O)C)=NC(CCC=2C=CC(NCCNC(=O)OC(C)(C)C)=CC=2)=C1 NQXOWXNWMRRJAC-UHFFFAOYSA-N 0.000 description 1
- CSMYRTHSSCOTKZ-UHFFFAOYSA-N tert-butyl n-[2-[4-[2-[2-acetamido-5-[(4-methylsulfonylphenyl)methyl]-1,3-thiazol-4-yl]ethyl]anilino]-2-oxoethyl]carbamate Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1CC=1SC(NC(=O)C)=NC=1CCC1=CC=C(NC(=O)CNC(=O)OC(C)(C)C)C=C1 CSMYRTHSSCOTKZ-UHFFFAOYSA-N 0.000 description 1
- YLVRJYGMUAOCPB-UHFFFAOYSA-N tert-butyl n-[2-[4-[3-(2-acetamido-1,3-thiazol-4-yl)propyl]phenyl]ethyl]carbamate Chemical compound S1C(NC(=O)C)=NC(CCCC=2C=CC(CCNC(=O)OC(C)(C)C)=CC=2)=C1 YLVRJYGMUAOCPB-UHFFFAOYSA-N 0.000 description 1
- FVRSSSANMJHFAZ-UHFFFAOYSA-N tert-butyl n-[4-[2-[2-acetamido-5-[methoxy(methyl)carbamoyl]-1,3-thiazol-4-yl]ethyl]phenyl]carbamate Chemical compound S1C(NC(C)=O)=NC(CCC=2C=CC(NC(=O)OC(C)(C)C)=CC=2)=C1C(=O)N(C)OC FVRSSSANMJHFAZ-UHFFFAOYSA-N 0.000 description 1
- JPURVODKBRBQHZ-UHFFFAOYSA-N tert-butyl n-[[(2-methylpropan-2-yl)oxycarbonylamino]-pyrazol-1-ylmethyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(NC(=O)OC(C)(C)C)N1C=CC=N1 JPURVODKBRBQHZ-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004904196 | 2004-07-27 | ||
| AU2004904196A AU2004904196A0 (en) | 2004-07-27 | Thiazole Derivatives Having VAP-1 Inhibitory Activity | |
| PCT/JP2005/014136 WO2006011631A2 (en) | 2004-07-27 | 2005-07-27 | Thiazole derivatives having vap-1 inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2575411A1 true CA2575411A1 (en) | 2006-02-02 |
Family
ID=35734947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002575411A Abandoned CA2575411A1 (en) | 2004-07-27 | 2005-07-27 | Thiazole derivatives having vap-1 inhibitory activity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070254931A1 (https=) |
| EP (1) | EP1786792B1 (https=) |
| JP (1) | JP4978464B2 (https=) |
| KR (1) | KR20070050932A (https=) |
| CN (1) | CN101031555A (https=) |
| AT (1) | ATE427941T1 (https=) |
| CA (1) | CA2575411A1 (https=) |
| DE (1) | DE602005013793D1 (https=) |
| ES (1) | ES2324922T3 (https=) |
| WO (1) | WO2006011631A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8748627B2 (en) | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| CN101384568B (zh) * | 2006-02-15 | 2012-12-12 | 雅培制药有限公司 | 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| EP2599498A1 (en) | 2007-06-25 | 2013-06-05 | R-Tech Ueno, Ltd. | Composition for ophthalmic disease associated with hypoxia or ischemia |
| US20100210697A1 (en) * | 2007-10-19 | 2010-08-19 | R-Tech Ueno, Ltd. | Pharmaceutical composition for treatment of cataract |
| WO2009061830A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Eye & Ear Infirmary | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
| JP5480819B2 (ja) * | 2008-01-18 | 2014-04-23 | アラーガン インコーポレイテッド | 選択的サブタイプアルファ２アドレナリンアゴニスト及びその使用方法 |
| TWI437986B (zh) | 2008-01-31 | 2014-05-21 | R Tech Ueno Ltd | 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途 |
| TWI490214B (zh) | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途 |
| NZ592603A (en) * | 2008-10-21 | 2013-02-22 | Metabolex Inc | Aryl gpr120 receptor agonists and uses thereof |
| UA112154C2 (uk) | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
| FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
| SG193307A1 (en) | 2011-03-15 | 2013-10-30 | Astellas Pharma Inc | Guanidine compound |
| US8921576B2 (en) | 2011-10-19 | 2014-12-30 | Kowa Company, Ltd. | Spiroindoline compound, and medicinal agent comprising same |
| WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| EP3131539B1 (en) | 2014-04-15 | 2018-12-05 | Pécsi Tudományegyetem | Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation |
| WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
| CN104478828B (zh) * | 2014-12-10 | 2016-07-06 | 漳州片仔癀药业股份有限公司 | 2-氨基-7-取代苯并噻唑类化合物及其制备方法与用途 |
| JO3546B1 (ar) * | 2015-01-09 | 2020-07-05 | Kyowa Kirin Co Ltd | طريقة لإنتاج مشتق ثيازول |
| JP2018076236A (ja) | 2015-06-05 | 2018-05-17 | 株式会社アールテック・ウエノ | がんを処置するための医薬組成物 |
| US10759781B2 (en) | 2015-08-06 | 2020-09-01 | Ube Industries, Ltd. | Substituted guanidine derivatives |
| HK1256174A1 (zh) | 2015-12-07 | 2019-09-13 | Benevolentai Cambridge Limited | 用於治疗疼痛的 vap-1 抑制剂 |
| ES2844926T3 (es) * | 2016-05-12 | 2021-07-23 | Boehringer Ingelheim Int | Derivados de piridinilo, composiciones farmacéuticas y usos de los mismos como inhibidores de AOC3 |
| CN110114350B (zh) | 2016-12-28 | 2022-03-04 | 宇部兴产株式会社 | 取代胍化合物 |
| US10213306B2 (en) | 2017-03-31 | 2019-02-26 | Neochord, Inc. | Minimally invasive heart valve repair in a beating heart |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3264595D1 (en) * | 1981-01-08 | 1985-08-14 | Mitsui Toatsu Chemicals | N-(4-phenyl-2-thiazolyl)carbamate derivatives, process for their preparation, and medicinal composition containing same |
| US4699928A (en) * | 1984-07-13 | 1987-10-13 | Merrell Dow Pharmaceuticals Inc. | Fluoroallylamine derivatives |
| IT1181871B (it) * | 1985-04-01 | 1987-09-30 | Consiglio Nazionale Ricerche | Inibitori selettivi delle benzilamminossidasi rispetto ad altre amminossidasi |
| US4916151A (en) * | 1985-12-05 | 1990-04-10 | Merrell Dow Pharmaceuticals Inc. | Method of treating parkinson's syndrome |
| US4650907A (en) * | 1985-12-05 | 1987-03-17 | Merrell Dow Pharmaceuticals Inc. | Nonaromatic fluoroallylamine MAO inhibitors |
| US5021456A (en) * | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4943593A (en) * | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4965288A (en) * | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5059814A (en) * | 1988-11-30 | 1991-10-22 | The California Institute Of Technology | Winner-take-all circuits for neural computing systems |
| JPH0848664A (ja) * | 1994-08-05 | 1996-02-20 | Hisamitsu Pharmaceut Co Inc | 新規なグアニジノ安息香酸エステル誘導体 |
| GB9506188D0 (en) * | 1995-03-27 | 1995-05-17 | Fujisawa Pharmaceutical Co | Amidine derivatives |
| JP2004502682A (ja) * | 2000-07-05 | 2004-01-29 | バイオティ セラピーズ コーポレイション | 銅含有アミン・オキシダーゼの阻害剤 |
| WO2002038153A1 (en) * | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
| EP1587800A1 (en) * | 2003-01-27 | 2005-10-26 | Astellas Pharma Inc. | Thiazole derivatives and their use as vap-1 inhibitors |
| JP4758337B2 (ja) * | 2003-03-31 | 2011-08-24 | 株式会社アールテック・ウエノ | 血管透過性亢進疾患を治療する方法 |
| WO2005089755A1 (en) * | 2004-03-18 | 2005-09-29 | R-Tech Ueno, Ltd. | Aqueous composition comprising thiazole derivative |
-
2005
- 2005-07-27 DE DE602005013793T patent/DE602005013793D1/de not_active Expired - Lifetime
- 2005-07-27 KR KR1020077004487A patent/KR20070050932A/ko not_active Ceased
- 2005-07-27 US US11/572,772 patent/US20070254931A1/en not_active Abandoned
- 2005-07-27 WO PCT/JP2005/014136 patent/WO2006011631A2/en not_active Ceased
- 2005-07-27 EP EP05768525A patent/EP1786792B1/en not_active Expired - Lifetime
- 2005-07-27 ES ES05768525T patent/ES2324922T3/es not_active Expired - Lifetime
- 2005-07-27 CA CA002575411A patent/CA2575411A1/en not_active Abandoned
- 2005-07-27 JP JP2007504792A patent/JP4978464B2/ja not_active Expired - Fee Related
- 2005-07-27 AT AT05768525T patent/ATE427941T1/de not_active IP Right Cessation
- 2005-07-27 CN CNA200580031703XA patent/CN101031555A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1786792A2 (en) | 2007-05-23 |
| ES2324922T3 (es) | 2009-08-19 |
| JP2008508188A (ja) | 2008-03-21 |
| WO2006011631A2 (en) | 2006-02-02 |
| WO2006011631A3 (en) | 2006-04-20 |
| DE602005013793D1 (de) | 2009-05-20 |
| US20070254931A1 (en) | 2007-11-01 |
| EP1786792B1 (en) | 2009-04-08 |
| JP4978464B2 (ja) | 2012-07-18 |
| ATE427941T1 (de) | 2009-04-15 |
| KR20070050932A (ko) | 2007-05-16 |
| CN101031555A (zh) | 2007-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1786792B1 (en) | Thiazole derivatives having vap-1 inhibitory activity | |
| JP2008508188A5 (https=) | ||
| US7442715B2 (en) | Thiazole derivatives | |
| EP1608365B1 (en) | Method for treating vascular hyperpermeable disease | |
| AU2009209885B2 (en) | Thiazole derivative and use thereof as VAP-1 inhibitor | |
| AU2017245679B2 (en) | Aminothiazole derivatives useful as antiviral agents | |
| HU228960B1 (hu) | Ftalazinon-származékok | |
| US20080015202A1 (en) | Thiazole Derivatives Having Vap-1 Inhibitory Activity | |
| ES2220504T3 (es) | Derivados del aminotiazol y su uso como ligandos receptores de crf. | |
| JP2008512346A5 (https=) | ||
| US10689374B1 (en) | Pyrimidine-thiazolidinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130729 |